Investing.com - Achilles Therapeutics (NASDAQ: ACHL) reported second quarter EPS of $-0.42, worse than the analyst estimate of $-0.42. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Achilles Therapeutics's stock price closed at $1.00. It is up 4.16% in the last 3 months and down -66.44% in the last 12 months.
Achilles Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Achilles Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Achilles Therapeutics's Financial Health score is "fair performance".
Check out Achilles Therapeutics's recent earnings performance, and Achilles Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar